Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFT1946 in BRAF V600 mutant solid tumors
NCT05668585Phase 1Completed
- Sponsor
- C4 Therapeutics
- Start
- Dec 2022
- Primary completion
- Nov 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 5
01
Overview
Phase 1, open-label trial of tagarafdeg in melanoma, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 2 more (6 arms), sponsored by C4 Therapeutics. Primary endpoints: Adverse Events, Dose Limiting Toxicities at 28 days and 6 more. Started Dec 2022; status: completed.
02
Drugs
tagarafdeg
03
Conditions
melanomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)anaplastic thyroid cancer (ATC)solid tumor
Beyond the preview
Go deeper on NCT05668585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668585.